Exelixis, Inc. (EXEL) stock
EXELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends January 1
Financials through Q3 FY2026, quarter ended Oct 2, 2026Last filing: 10-Q on Oct 29, 2026Score 18/301% above fair value
$69.00−0.84 (-1.20%)
Close on Nov 13, 2026Market cap $16.84BP/E 20.7Yield –
Exelixis enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Exelixis's enterprise value was $16.76B on Nov 11, 2026, against $10.85B a year earlier. Over the last 5 years it ranged from $3.50B to $16.76B, with a median of $6.19B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $16.76B | +55.7% |
| 2025 | Dec 31, 2025 | $10.76B | +29.2% |
| 2024 | Dec 31, 2024 | $8.33B | +31.0% |
| 2023 | Dec 29, 2023 | $6.36B | +75.4% |
| 2022 | Dec 30, 2022 | $3.63B | -16.6% |
| 2021 | Dec 31, 2021 | $4.35B | -13.4% |
| 2020 | Dec 31, 2020 | $5.02B | +9.4% |
| 2019 | Dec 31, 2019 | $4.59B | -12.5% |
| 2018 | Dec 31, 2018 | $5.24B | -39.2% |
| 2017 | Dec 29, 2017 | $8.62B | +107.1% |
| 2016 | Dec 30, 2016 | $4.16B | +186.0% |
| 2015 | Dec 31, 2015 | $1.46B | +227.6% |
| 2014 | Dec 31, 2014 | $444.27M | -62.7% |
| 2013 | Dec 31, 2013 | $1.19B | +165.3% |
| 2012 | Dec 31, 2012 | $449.08M | -49.4% |
| 2011 | Jul 29, 2011 | $887.31M | +12.0% |
| 2010 | Dec 31, 2010 | $792.27M | – |
See a number that looks wrong?